The Genetics of Osteosarcoma

Sarcoma · 2012 · Classic · cited 254 times

Jeff W. Martin, Jeremy A. Squire, Maria Zieleńska

Department of Paediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Canada M5G 1X8

Orthopaedic Oncology Pediatric Orthopaedics

SUMMARY — THE REDUCTIONOsteosarcoma has a complex, heterogeneous genomic landscape with recurrent copy number alterations but no definitive oncogene or tumor suppressor target yet identified for therapeutic exploitation.
Abstract, as published

Osteosarcoma is a primary bone malignancy with a particularly high incidence rate in children and adolescents relative to other age groups. The etiology of this often aggressive cancer is currently unknown, because complicated structural and numeric genomic rearrangements in cancer cells preclude understanding of tumour development. In addition, few consistent genetic changes that may indicate effective molecular therapeutic targets have been reported. However, high-resolution techniques continue to improve knowledge of distinct areas of the genome that are more commonly associated with osteosarcomas. Copy number gains at chromosomes 1p, 1q, 6p, 8q, and 17p as well as copy number losses at chromosomes 3q, 6q, 9, 10, 13, 17p, and 18q have been detected by numerous groups, but definitive oncogenes or tumour suppressor genes remain elusive with respect to many loci. In this paper, we examine studies of the genetics of osteosarcoma to comprehensively describe the heterogeneity and complexity of this cancer.

Featured in the 2026-06-23 issue.

← Comparative analysis of pelvic/sacral versus vertebral chordo…Diagnostic errors in musculoskeletal oncology and possible mi… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.